Grant: Proof of Principle Program - Phase II
University of British Columbia
$300,000.00
A defined cyclic peptide epitope specific to Abeta oligomers: Active and passive vaccination in mouse models of Alzheimer's disease
EF 2012-13
Résumé
Alzheimer's disease (AD), the most common cause of adult-onset dementia, is a major threat to the autonomy, mobility, and overall functionality of persons in the developed world. UBC scientists have identified and characterized a defined specific target for Abeta oligomers, known to be toxic in Alzheimer's disease. Cangene Corporation, a Canadian biotechnology company, has licensed the technology to develop antibody treatments for Alzheimer's. UBC and Cangene will now establish efficacy in mouse models of the disease by testing active vaccination and passive injection with oligomer-specific epitope and antibodies, respectively.
Programme
Proof of Principle Program - Phase II
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
268560
Name
Cashman Neil R
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cangene Corporation (Winnipeg, MB); Cangene Corporation (Winnipeg, MB)
Instname2
Aging
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
A defined cyclic peptide epitope specific to Abeta oligomers: Active and passive vaccination in mouse models of Alzheimer's disease
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$300,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase II
Keyworddelim
Alzheimer'S Disease; Amyloid Beta (Abeta); Conformation-Specific Antibodies; Immunotherapies; Oligomers; Vaccines
Abstract
Alzheimer's disease (AD), the most common cause of adult-onset dementia, is a major threat to the autonomy, mobility, and overall functionality of persons in the developed world. UBC scientists have identified and characterized a defined specific target for Abeta oligomers, known to be toxic in Alzheimer's disease. Cangene Corporation, a Canadian biotechnology company, has licensed the technology to develop antibody treatments for Alzheimer's. UBC and Cangene will now establish efficacy in mouse models of the disease by testing active vaccination and passive injection with oligomer-specific epitope and antibodies, respectively.
Competitiondate
201209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cashman, Neil R
Approvedterm
1 an 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $300,000~ $0~
